Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder. For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Changing the Landscape

Tonix Pharmaceuticals is developing next-generation medicines to help important public health challenges.

Tonix's lead drug candidate was granted Breakthrough Therapy designation by the FDA for the treatment of posttraumatic stress disorder (PTSD).

Learn more

Latest News

Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease

• July 16, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that the U.S. Food and Drug Administration (FDA)…

Management Team

Our experienced team has a strong track record of success in drug approvals and value creation.

View Management

Clinical Pipeline

Tonix's lead product candidate, Tonmya, is being developed for the treatment of PTSD.

View Pipeline

About Tonix Pharmaceuticals

Tonix is developing innovative pharmaceutical products to address important public health challenges, with two programs focusing on posttraumatic stress disorder (PTSD). PTSD is a serious condition characterized by chronic disability, inadequate treatment options, and overall high utilization of healthcare services creating significant economic burden. Other development programs include TNX-801, a potential smallpox-preventing vaccine.